Ato*Bio is a late stage biotechnology company that develops novel immunomodulators for critically ill patients.
Reltecimod, Ato*Bio’s lead product, is initially being developed to treat Necrotizing Soft Tissue Infections (NSTI), a rare, life threatening infection with high morbidity and mortality.
Reltecimod is currently being studied in ACCUTE (Reltecimod Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions) , a phase 3 clinical trial evaluating its efficacy in patient with NSTI. Previously, Reltecimod completed a phase 2 study in NSTI. Results demonstrated that patients treated with Reltecimod had a meaningful improvement across multiple end points.